Figure 4.

A possible immune deviation after daratumumab and plerixafor treatment. (A) Ratio of CD8 to CD4 was not changed after desensitization with daratumumab and plerixafor in blood and lymph nodes. (B) Ratio of CD8 cells to Treg cells show a strong increasing trend (P=0.06) in the lymph nodes but not in the blood. (C) Transitional B cell population (CD20⁺CD24⁺CD38⁺) showed a strong trend of reduction (P=0.08). (D) Increased frequencies of activated T (CD69⁺) cells after kidney transplantation. The results are representative of four monkeys tested individually. LN, lymph node.